search results for: dealforma

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

Last year
Financing
Special

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the ...

4 years ago
Deals

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

10 months ago

What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

3 years ago
Startups
Deals

Scoop: GSK’s ven­ture team at SR One in talks to spin off from its big phar­ma founder, now un­der new R&D man­age­ment

5 years ago
Financing
Pharma

IPOs and ven­ture in­vest­ing rock on in Q2 as SPAC at­tack takes a break. But what hap­pened to the deals and M&A?

Last year
Bioregnum

When times got tough, the bio­phar­ma in­dus­try hit the Zoom but­ton and kept things mov­ing at a multi­bil­lion-dol­lar clip

3 years ago
Deals

Or­biMed's TKI play makes its Nas­daq de­but as The­seus prices IPO

Last year
Financing

Roche joins the M&A game, buy­ing gene ther­a­py pi­o­neer Spark for $4.3B

4 years ago
Deals
Cell/Gene Tx

#BIO22: By the Num­bers: Af­ter the mu­sic died, you can see some en­cour­ag­ing signs on the M&A and li­cens­ing fronts. But ...

8 months ago
Deals

Q1: A flood of in­vestor cash drove biotech's num­bers to new record highs, and the tor­rent of cash is mov­ing up­stream ...

Last year
Deals

The top 20 pre­clin­i­cal biotech deals ranked by cash up­front re­veals 3 big play­ers — and some ma­jor league stinkers

4 years ago
Deals
Discovery

Which big bio­phar­ma play­er should gam­ble $34B on a ripe rare-dis­ease M&A tar­get? An ac­tion-hun­gry top an­a­lyst fills ...

3 years ago
Deals

Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

4 years ago
Pharma

Sanofi buys mR­NA play­er Trans­late Bio for $3.2B. And the price fits a pop­u­lar range for biotech M&A

Last year
Deals

Is the biotech boom start­ing to fade? The roar­ing ‘20s starts to look a lit­tle fa­tigued. Plus: Top 5 deals, IPOs, ...

Last year
Deals
Bioregnum

Who's do­ing deals in the midst of a crip­pling pan­dem­ic? Here are the top 10 play­ers for March

3 years ago
Deals

Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO ...

Last year
Deals
First page Previous page 12345 Next page Last page

latest

Most read

Up­dat­ed: R&D tur­bu­lence at Bris­tol My­ers now in­cludes the end of a $650M al­liance and the de­par­ture of a top re­search ...

2 days ago
Bioregnum

Ex­clu­sive: Ver­i­ly wel­comes Atara Bio­ther­a­peu­tics vet­er­an as new CFO

5 hours ago
People
Pharma

Dex­com's spokescelebri­ty Nick Jonas re­turns to Su­per Bowl in new glu­cose mon­i­tor com­mer­cial

6 hours ago
Pharma
Marketing

New Te­va CEO Richard Fran­cis repri­or­i­tizes to 'get back to growth'

6 hours ago
Pharma

DC court over­rules PhRMA's bid to shut down drug im­ports from Cana­da

6 hours ago
Pharma
Law
see latest stream